ALBIOMA SA (ABIO.PA)       49.98  +0.14 (+0.28%)

49.98  +0.14 (+0.28%)

FR0000060402 - Common Stock


Fundamental Rating

Taking everything into account, ABIO scores 5 out of 10 in our fundamental rating. ABIO was compared to 11 industry peers in the Independent Power and Renewable Electricity Producers industry. Both the profitability and the financial health of ABIO get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, ABIO is valued expensive at the moment.




Profitability

Profitability Rating


ABIO has a Return On Assets of 3.14%. This is amongst the best returns in the industry. The industry average is 1.13%. ABIO outperforms 100% of its industry peers.
ABIO has a Return On Equity of 11.73%. This is better than the industry average of 9.38%.

ABIO's Profit Margin of 10.30% is in line with the rest of the industry. The industry average Profit Margin is 12.29%.
The Piotroski-F score of ABIO is 6.00. This is a neutral score and indicates average health and profitability for ABIO.
VS Industry

ROA (3.14%) VS Industry: 100% outperformed.

-120.00
3.14

ROE (11.73%) VS Industry: 71% outperformed.

0.35
20.89

Profit Margin (10.3%) VS Industry: 44% outperformed.

-4.61
27.38

Valuation

Valuation Rating


ABIO's Price/Earning Ratio is rather cheap when compared to the industry average which is at 32.97. ABIO is also cheaper than 83% of the companies in the same industry.
When comparing the current price to the book value of ABIO, we can conclude it is valued correctly. It is trading at 3.21 times its book value.
Compared to an average industry Enterprise Value to EBITDA ratio of 11.89, ABIO is valued in line with its industry peers.
With a Price/Earnings Ratio of 27.31, ABIO can be considered very expensive at the moment.

With a Forward Price/Earnings Ratio of 26.75, ABIO is valued very expensively.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
Compared to an average industry price book ratio of 3.14, ABIO is valued more expensive than its industry peers.
VS Industry

Price/Earnings (27.31) VS Industry: 83% outperformed.

105.26
13.55

Price/Book (3.21) VS Industry: 40% outperformed.

38.41
1.90

Enterprise Value/ EBITDA (11.89) VS Industry: 50% outperformed.

21.28
5.76

Growth

Growth Rating


Measured over the past 5 years, ABIO shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.59% on average per year.
The Revenue has grown by 13.13% in the past year. This is quite good.
ABIO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.41%.
Based on estimates for the next 5 years, ABIO will show a small growth in Earnings Per Share. The EPS will grow by 7.58% on average per year.

The Revenue has been growing slightly by 9.28% on average over the past 5 years.
Based on estimates for the next 5 years, ABIO will show a small growth in Revenue. The Revenue will grow by 6.22% on average per year.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS10.59% 8.33% 6.41% 3.15% 10.38% 7.07% 7.58%
Revenue9.28% 10.21% 13.13% 8.28% 6.4% 6.91% 6.22%

Health

Health Rating


The Current Ratio of ABIO is much better than the industry average of 1.00.
ABIO has one of the better Altman-Z scores in its industry. It is much better than the industry average of 1.19. ABIO has a better score than 100% of its industry peers.
A Current Ratio of 1.17 indicates that ABIO should not have too much problems paying its short term obligations.
The Piotroski-F score of ABIO is 6.00. This is a neutral score and indicates average health and profitability for ABIO.

ABIO has a Quick Ratio of 1.17. This is a bad value and indicates that ABIO is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Quick Ratio of ABIO to the average industry Current Ratio of 0.90, ABIO is less able to pay its short term obligations than its industry peers.
When comparing the Debt to Equity Ratio of ABIO to the average industry Debt to Equity Ratio of 1.31, ABIO required more debt to finance its operations than its industry peers.
ABIO has an Altman-Z score of 1.61. This is a bad value and indicates that ABIO is not financially healthy and even has some risk of bankruptcy.
VS Industry

Debt/Equity (1.79) VS Industry: 30% outperformed.

2.57
0.00

Quick Ratio (0.89) VS Industry: 30% outperformed.

0.33
15.89

Current Ratio (1.17) VS Industry: 70% outperformed.

0.33
15.94

Altman-Z (1.61) VS Industry: 100% outperformed.

-212.84
1.61

Dividend

Dividend Rating


Compared to an average industry Dividend Yield of 1.50, ABIO pays a bit more dividend than its industry peers.
On average, the dividend of ABIO grows each year by 8.92%, which is quite nice.
31.21% of the earnings are spent on dividend by ABIO. This is a low number and sustainable payout ratio.

With a Yearly Dividend Yield of 1.68%, ABIO has a reasonable but not impressive dividend return.
The dividend of ABIO is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
ABIO's Dividend Yield is slightly below the S&P500 average, which is at 2.18.
VS Industry

Dividend Yield (1.68%) VS Industry: 66% outperformed.

0.26
2.50
ABIO Daily chart

ALBIOMA SA49.98

EPA:ABIO (5/27/2022, 5:29:49 PM)+0.14 (+0.28%)

Chartmill FA Rating
GICS Sector Utilities
GICS IndustryGroup Utilities
GICS Industry Independent Power and Renewable Electricity Producers
Earnings (Last) N/A N/A Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners N/A
Market Cap 1.61B Analysts 80
Valuation
PE 27.31 Fwd PE 26.75
PEG (NY) 8.66 PEG (5Y) 2.58
P/S 2.82 P/B 3.21
EV/EBITDA 11.89
Profitability
ROA 3.14% ROE 11.73%
PM 10.3 Asset Turnover 0.31
Growth
EPS 1Y 6.41% EPS 3Y 8.33%
EPS 5Y 10.59% EPS growth Q2Q 16.36%
EPS Next Y 3.15% EPS Next 2Y 10.38%
EPS Next 3Y 7.07% EPS Next 5Y 7.58%
Revenue growth 1Y 13.13% Revenue growth 3Y 10.21%
Revenue growth 5Y 9.28% Revenue growth Q2Q 19.37%
Revenue Next Year 8.28% Revenue Next 2Y 6.4%
Revenue Next 3Y 6.91% Revenue Next 5Y 6.22%
Health
Current Ratio 1.17 Quick Ratio 0.89
Altman-Z 1.61 F-Score 6
Debt/Equity 1.79
Dividend
Dividend Yield 1.68% Dividend Growth 8.92%
DP 31.21% Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext